ALK and non-small cell lung carcinoma: In the absence of NGS testing (0% NGS) and assuming 80% of patients undergo SGT, a total of 15.2% of patients with nonsquamous NSCLC harboring an ADO were identified out of the total estimated 19% positive for EGFR or ALK mutations.